Drugs that contain Azilsartan Kamedoxomil
1. Edarbi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 1 month from now) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(4 years from now) | |
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage
EDARBI family patents
